Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies Many HTAs in Europe are seen as conservative and even reactionary when it comes to innovating or changing their processes. However, Amr's PhD thesis is a 300+ page ‘how to’ manual highlighting RWE best practices [...]
Podcast - Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit In this podcast, Steve Bates, the UK BioIndustry Association's CEO, discusses both the challenges and opportunities of Brexit on the UK’s biotechnology sector, and the need for strong, vital IP supported by private investment.Steve was an advisor to [...]
4 December 2018 - 2.00-3.00pm CET, 8.00-9.00am ET In this webinar we: • Highlight the results of the research • Expand on the datapackage used • Discuss the gap between EU and US IP productivity in healthcare • Address the need for IP in the global biotech sector
Podcast - Better Science, Better Health: The US Chamber's Patrick Kilbride on the Rapidly Changing IP World Patrick Kilbride is vice president of international intellectual property for the Global Innovation Policy Center (GIPC) at the U.S. Chamber of Commerce. Over the last several years, there has been a growing chorus of voices [...]
Podcast - Better Science, Better Health: Stirring the IP Pot Emil Pot was one of the founders of ActoGeniX, which was successfully acquired in 2015 by Intrexon. Emil outlines the ingredients Europe needs to build a company from scratch, and leverage home-grown Intellectual Property.
Press Room From: Morning Health Care Europe <morninghealth@politico.eu> Date: Fri, 5 Oct 2018 at 06:57 Subject: POLITICO Pro Morning Health Care: After Austria comes Romania — Cancer research cash To: POLITICO Europe Subscribers https://www.politico.eu/pro/politico-pro-morning-health-care-after-austria-comes-romania-cancer-research-cash-trans-fats/?utm_source=POLITICO.EU&utm_campaign=0abbd30995-EMAIL_CAMPAIGN_2018_10_04_08_23&utm_medium=email&utm_term=0_10959edeb5-0abbd30995-189777477 RESEARCH — DOES COMMISSION FUNDING MATTER? A study presented Thursday at Gastein made the argument that private funding correlates [...]
Podcast - Better Science, Better Health: VIB’s Johan Cardoen, An EU Biotech Success Story For the first podcast in our series investigating the impact and importance of IP on European biotech and innovation, we have an in-depth discussion with Johan Cardoen of VIB, Gent’s life sciences research institute in Belgium. VIB has been called by Reuters, “part [...]
Vital Transformation leads a new consortia investigating the relationship between public funding and private investment into new innovative therapies and the supporting system of IP. This project will develop original research investigating the success factors that create successful EU biotech companies and communicate the importance of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that succeed.
ARM is the leading international advocacy organization representing the gene and cell therapy sector and consists of more than 290 members, including life sciences companies, patient advocacy groups, academic research institutions, and investors.
4 October, 7.30-8.45 CET, Bad Hofgastein
This breakfast session will offer an open debate on the role of IP in EU healthcare innovation, focused on the appropriate role and balance for both public funding and private investments, supported by new research on EU biotech success factors produced by Vital Transformation. Speakers will discuss in a pro-con format whether IP is a problem or a solution to our healthcare needs, and what role the EU will play in supporting next-generation health technologies to promote a sustainable R&D infrastructure in Europe.